(19)
(11) EP 1 392 287 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.01.2007 Bulletin 2007/02

(45) Mention of the grant of the patent:
22.11.2006 Bulletin 2006/47

(21) Application number: 02774113.1

(22) Date of filing: 22.05.2002
(51) International Patent Classification (IPC): 
A61K 31/397(2006.01)
 A61P 25/28(2006.01)
(86) International application number:
PCT/US2002/016306
(87) International publication number:
WO 2002/096415 (05.12.2002 Gazette 2002/49)

(54)

Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease

Verwendung von substituierten Azetidinonderivaten in der Behandlung der Alzheimer-Krankheit

Usage de dérivés de l'azétidinone pour le traitement de la maladie d' Alzheimer.

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 25.05.2001 US 293651 P
21.09.2001 US 323911 P

(43) Date of publication of application:
03.03.2004 Bulletin 2004/10

(73) Proprietor: SCHERING CORPORATION
Kenilworth, New Jersey 07033-0530 (US)

(72) Inventors:
  • DAVIS, Harry, R.
    Berkeley Heights, NJ 07922 (US)
  • PARKER, Eric, McFee
    Scotch Plains, NJ 07076 (US)
  • VAN HEEK, Margaret
    Scotch Plains, NJ 07076 (US)
  • WONG, Gwendolyn, Tse
    Lexington, MA 02421 (US)
  • MERKEL, Laura, B.
    Princeton, NJ 08540 (US)

(74) Representative: HOFFMANN EITLE 
Patent- und Rechtsanwälte Arabellastrasse 4
81925 München
81925 München (DE)


(56) References cited: : 
WO-A-95/08532
WO-A-97/41098
 WO-A-97/21676
WO-A-99/38498
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).